Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis Feb 13, 2023
Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA Jan 25, 2023
Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia Jan 9, 2023
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis Dec 6, 2022
Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances Nov 7, 2022
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update Nov 4, 2022
Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA) Nov 2, 2022
Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting Oct 24, 2022